Population Pharmacokinetics of Piperacillin in Non-Critically Ill Patients with Bacteremia Caused by Enterobacteriaceae
Authors:
- Vicente Merino-BohórquezVMVicente Merino-Bohórquez
- Fernando Docobo-PérezFDFernando Docobo-Pérez
- Adoración Valiente-MéndezAVAdoración Valiente-Méndez
- Mercedes Delgado-ValverdeMDMercedes Delgado-Valverde
- Manuel CameánMCManuel Cameán
- William W. HopeWHWilliam W. Hope
- Álvaro PascualÁPÁlvaro Pascual
- Jesús Rodríguez-BañoJRJesús Rodríguez-Baño
Open Access
- 25 March 2021
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 10 (4) , 348
Abstract
This study analyzes the pharmacokinetic variability of piperacillin in non-critically ill patients with Enterobacteriaceae bloodstream infections (EBSI) and explores predicted clinical outcomes and piperacillin-related neurotoxicity under different renal conditions. Hospitalized, non-critically ill patients treated with piperacillin–tazobactam for EBSI were included. Four serum samples per patient were collected and analyzed. A population pharmacokinetic model was developed using the Pmetrics package for R. Monte Carlo simulations of various dosage regimens of 4 g piperacillin, administered q8 h or q12 h by short (0.5 h) or long (4 h) infusion, following the different glomerular filtration rate (GFR) categories used to classify chronic kidney disease (Kidney Disease: Improving Global Outcomes, KDIGO) to determine the probability of target attainment (PTA) using a free drug concentrations above the minimal inhibitory concentration (fT > MIC) of 50% for efficacy and targets for piperacillin-associated neurotoxicity. Twenty-seven patients (102 samples) were included. Extended piperacillin infusions reached a PTA > 90% (50%fT > MIC) within the susceptibility range, although a loading dose did not greatly improve the expected outcome. Long infusions reduced the expected toxicity in patients with severe renal impairment. The study supports the use of extended infusions of piperacillin in non-critically ill patients with EBSI. No benefits of a loading dose were expected in our population. Finally, extended infusions may reduce the risk of toxicity in patients with severe renal impairment.Keywords
Funding Information
- Instituto de Salud Carlos III (PI10/02021)
- European Regional Development Fund (“A way to achieve Europe”, Operative Programme Intelligent Growth 2014‐ 2020.)
This publication has 36 references indexed in Scilit:
- Clinical Outcomes With Extended or Continuous Versus Short-term Intravenous Infusion of Carbapenems and Piperacillin/Tazobactam: A Systematic Review and Meta-analysisClinical Infectious Diseases, 2012
- Continuous Infusion of Beta-Lactam Antibiotics in Severe Sepsis: A Multicenter Double-Blind, Randomized Controlled TrialClinical Infectious Diseases, 2012
- Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort studyBMC Infectious Diseases, 2012
- Population Pharmacokinetics of Extended-Infusion Piperacillin-Tazobactam in Hospitalized Patients with Nosocomial InfectionsAntimicrobial Agents and Chemotherapy, 2012
- Impact of Inadequate Empirical Therapy on the Mortality of Patients with Bloodstream Infections: a Propensity Score-Based AnalysisAntimicrobial Agents and Chemotherapy, 2012
- First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsisInternational Journal of Antimicrobial Agents, 2010
- Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in LungsAntimicrobial Agents and Chemotherapy, 2009
- Piperacillin-Tazobactam for Pseudomonas aeruginosa Infection: Clinical Implications of an Extended-Infusion Dosing StrategyClinical Infectious Diseases, 2007
- Randomized, Open-Label, Comparative Study of Piperacillin-Tazobactam Administered by Continuous Infusion versus Intermittent Infusion for Treatment of Hospitalized Patients with Complicated Intra-Abdominal InfectionAntimicrobial Agents and Chemotherapy, 2006
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976